According to Benzinga Pro, BioNTech's peer group average for short interest as a percentage of float is 5.26%, which means ...

Shares of Moderna Inc (BMV:MRNA) (NASDAQ:MRNA) climbed 5.4% mid-day Tuesday as remarks by RFK Jr, who clarified his stance as not being anti-vaccine or anti-industry, appeared to bolster investor ...

Ahead of his Senate confirmation hearing this week, Robert F. Kennedy Jr., President Donald Trump’s nominee to lead the Department of Health and Human Services (HHS), has said he’s not “anti-vaccine ...

Fla., praised news that President Donald Trump will reinstate service members expelled for refusing to take the COVID-19 ...

In a report released today, Jessica Fye from J.P. Morgan maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a price target ...

These are unquestionably serious issues, but Merck remains a top stock to buy and hold, at least for investors focused on the long game. Here's why. Merck's Keytruda generates over $20 billion in ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.

Atomi Financial Group Inc. raised its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 6.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional ...

SINGAPORE - People who are eligible for the Novavax Covid-19 vaccine can go to selected clinics from Jan 24 to April 30 for ...

We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

COVID-19 vaccines were not associated with increased risk for thyroid diseases but were associated with increased risk for exacerbated hypothyroidism.

Recent results raise hope of new "broad, pan-tumor platform" like Keytruda. The emerging drugs are bispecific antibodies that ...